个体化降脂治疗在杂合子家族性高胆固醇血症中广泛的黄瘤消退。

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE Clinica e Investigacion en Arteriosclerosis Pub Date : 2024-01-01 DOI:10.1016/j.arteri.2023.11.002

Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro

{"title":"个体化降脂治疗在杂合子家族性高胆固醇血症中广泛的黄瘤消退。","authors":"Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro","doi":"10.1016/j.arteri.2023.11.002","DOIUrl":null,"url":null,"abstract":"<div>“The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412 mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.</div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 1","pages":"Pages 35-37"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia\",\"authors\":\"Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro\",\"doi\":\"10.1016/j.arteri.2023.11.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>“The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412 mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.</div>\",\"PeriodicalId\":45230,\"journal\":{\"name\":\"Clinica e Investigacion en Arteriosclerosis\",\"volume\":\"36 1\",\"pages\":\"Pages 35-37\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica e Investigacion en Arteriosclerosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214916823000992\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214916823000992","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

摘要

“越低越好”是治疗高LDL胆固醇的推荐方法。不幸的是，这并不总是能够实现，例如一位69岁的女性因其脂质谱(低密度脂蛋白胆固醇412mg/dl)、双侧黄斑瘤和皮肤黄斑瘤而来到我们研究所。通过最大化和个性化的降脂治疗(瑞舒伐他汀、依泽替米贝、PCSK9i和脂蛋白分离)，仅仅6个月后，患者的皮肤黄瘤出现了令人印象深刻的消退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia

“The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412 mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica e Investigacion en Arteriosclerosis PERIPHERAL VASCULAR DISEASE-

CiteScore

3.20

自引率

6.20%

发文量

审稿时长

40 days

期刊介绍： La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.